UnknownPhase 4NCT03596957

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease

Studying Autosomal dominant polycystic kidney disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lisbet Brandi
Principal Investigator
Lisbet Brandi, MD DMSc MHM
KNEA, Nordsjaellands Hospital
Intervention
Tolvaptan(drug)
Enrollment
90 enrolled
Eligibility
18-65 years · All sexes
Timeline
20182020

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03596957 on ClinicalTrials.gov

Other trials for Autosomal dominant polycystic kidney disease

Additional recruiting or active studies for the same condition.

See all trials for Autosomal dominant polycystic kidney disease

← Back to all trials